^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P07.01: Sequencing of TKI With or Without Brain Radiotherapy (RT) in EGFR Mutated or ALK Rearranged Non-small Cell Lung Cancer (NSCLC) with Brain Metastases
Published date:
02/19/2021
Excerpt:
...study of patients diagnosed with metastatic NSCLC and BMs with either activating EGFR mutations or ALK rearrangements…The analysis aimed to evaluate outcomes in patients who received TKI alone versus stereotactic radiosurgery (SRS) followed by TKI versus whole brain radiotherapy (WBRT) followed by TKI. TKI therapy was separated by early (erlotinib, gefitinib, afatinib, crizotinib, or experimental) versus newer (osimertinib, alectinib, brigatinib, ensartinib, or lorlatinib) generation. In the EGFR mutated cohort, the use of newer generation TKIs and the presence of EGFR exon 19 deletion were associated with prolonged survival.
